| Non-Small Cell Lung Carcinoma
Imfinzi vs Abraxane
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Imfinzi vs Abraxane with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAbraxane has a higher rate of injection site reactions vs Imfinzi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Abraxane but not Imfinzi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Imfinzi
Abraxane
At A Glance
IV infusion
Every 2 to 4 weeks
PD-L1 antagonist
IV infusion
Weekly to every 3 weeks
Microtubule inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Small cell carcinoma of lung
- Biliary Tract Cancer
- Liver carcinoma
- Endometrial Carcinoma
- Carcinoma of bladder
- Stomach Carcinoma
- Gastroesophageal junction cancer
- Carcinoma breast stage IV
- Non-Small Cell Lung Carcinoma
- Adenocarcinoma of pancreas
Dosing
Resectable NSCLC Neoadjuvant: 1,500 mg IV every 3 weeks in combination with chemotherapy for up to 4 cycles prior to surgery (or 20 mg/kg if weight <30 kg). Adjuvant: 1,500 mg IV every 4 weeks as a single agent for up to 12 cycles after surgery (or 20 mg/kg if weight <30 kg).
Unresectable Stage III NSCLC 1,500 mg IV every 4 weeks or 10 mg/kg every 2 weeks as a single agent until disease progression or unacceptable toxicity (maximum 12 months) (or 10 mg/kg every 2 weeks if weight <30 kg).
Metastatic NSCLC 1,500 mg IV in combination with tremelimumab-actl 75 mg and platinum-based chemotherapy every 3 weeks for 4 cycles, then 1,500 mg every 4 weeks as a single agent with pemetrexed maintenance for non-squamous (or 20 mg/kg and 1 mg/kg tremelimumab-actl if weight <30 kg).
Limited Stage SCLC 1,500 mg IV every 4 weeks as a single agent until disease progression or unacceptable toxicity (maximum 24 months) (or 20 mg/kg if weight <30 kg).
Extensive Stage SCLC 1,500 mg IV every 3 weeks in combination with etoposide and carboplatin or cisplatin for 4 cycles, then 1,500 mg every 4 weeks as a single agent until disease progression (or 20 mg/kg if weight <30 kg).
Biliary Tract Cancer 1,500 mg IV every 3 weeks in combination with gemcitabine and cisplatin for up to 8 cycles, then 1,500 mg every 4 weeks as a single agent until disease progression (or 20 mg/kg if weight <30 kg).
Unresectable Hepatocellular Carcinoma 1,500 mg IV in combination with a single dose of tremelimumab-actl 300 mg at Cycle 1/Day 1, followed by 1,500 mg every 4 weeks as a single agent until disease progression (or 20 mg/kg and 4 mg/kg tremelimumab-actl if weight <30 kg).
dMMR Endometrial Carcinoma 1,120 mg IV in combination with carboplatin and paclitaxel every 3 weeks for 6 cycles, followed by 1,500 mg every 4 weeks as a single agent until disease progression (or 15 mg/kg followed by 20 mg/kg if weight <30 kg).
Muscle Invasive Bladder Cancer Neoadjuvant: 1,500 mg IV in combination with gemcitabine and cisplatin every 3 weeks for 4 cycles prior to surgery (or 20 mg/kg if weight <30 kg). Adjuvant: 1,500 mg IV every 4 weeks as a single agent for up to 8 cycles after surgery (or 20 mg/kg if weight <30 kg).
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma Neoadjuvant: 1,500 mg IV every 4 weeks with FLOT for up to 2 cycles prior to surgery (or 20 mg/kg if weight <30 kg). Adjuvant: 1,500 mg IV every 4 weeks with FLOT for up to 2 cycles, followed by 1,500 mg as a single agent every 4 weeks for up to 10 cycles (or 20 mg/kg if weight <30 kg).
Carcinoma breast stage IV 260 mg/m2 IV over 30 minutes every 3 weeks.
Non-Small Cell Lung Carcinoma 100 mg/m2 IV over 30 minutes on Days 1, 8, and 15 of each 21-day cycle; administer carboplatin on Day 1 of each 21-day cycle immediately after ABRAXANE.
Adenocarcinoma of pancreas 125 mg/m2 IV over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle; administer gemcitabine on Days 1, 8, and 15 of each 28-day cycle immediately after ABRAXANE.
Contraindications
—
- Baseline neutrophil count below 1500 cells/mm3
- History of severe hypersensitivity reaction to ABRAXANE
Adverse Reactions
Most common (>=10%) Nausea, fatigue, cough, pneumonitis, rash, diarrhea, decreased appetite, musculoskeletal pain, constipation, dyspnea, upper respiratory tract infections, pyrexia, pruritus, headache, vomiting, abdominal pain, hypothyroidism, peripheral neuropathy, alopecia, insomnia
Serious Pneumonitis, pneumonia, hepatitis, colitis, myocarditis, nephritis, endocrinopathies, infusion-related reactions, exfoliative dermatologic conditions
Postmarketing Not specified in label
Most common (>=20%) Alopecia, neutropenia, sensory/peripheral neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, diarrhea, thrombocytopenia, peripheral edema, pyrexia, vomiting, decreased appetite, rash, dehydration
Serious Anemia, pneumonia, pyrexia, dehydration, vomiting
Postmarketing Severe hypersensitivity reactions, congestive heart failure, left ventricular dysfunction, atrioventricular block, pneumonitis, interstitial pneumonia, pulmonary embolism, cranial nerve palsies, vocal cord paresis, autonomic neuropathy, cystoid macular edema, hepatic necrosis, intestinal obstruction, intestinal perforation, pancreatitis, ischemic colitis, tumor lysis syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis
Pharmacology
Durvalumab is a human IgG1 kappa monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, releasing the inhibition of immune responses without inducing antibody-dependent cell-mediated cytotoxicity.
ABRAXANE is a microtubule inhibitor that promotes assembly and stabilization of microtubules from tubulin dimers, inhibiting the normal dynamic reorganization of the microtubule network essential for vital interphase and mitotic cellular functions.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Imfinzi
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Abraxane
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Imfinzi
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Abraxane
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Imfinzi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Abraxane
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Imfinzi.
No savings programs available for Abraxane.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ImfinziView full Imfinzi profile
AbraxaneView full Abraxane profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.